Additionally, combination therapies targeting both PI3K and other pathways involved in neuroinflammation (e.g., mTOR, NF-κB) may offer a more comprehensive approach to managing neurodegenerative diseases. The gene discussed is PIK3CD; the disease is neurodegenerative disease.